stockrowAmylyx Pharmaceuticals, Inc. (AMLX) vs Lantheus Holdings, Inc. (LNTH)
- Amylyx Pharmaceuticals, Inc. AMLX 27.97 +1.27%
- Lantheus Holdings, Inc. LNTH 100.94 +0.24%
Amylyx Pharmaceuticals, Inc. and Lantheus Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Lantheus Holdings, Inc. is the larger, with a market value of $6.6B against $3.5B — 1.9× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Lantheus Holdings, Inc. trades at 24.3×. Lantheus Holdings, Inc. grew revenue faster over the last twelve months: 2.38% against −77.1%. Lantheus Holdings, Inc. has the higher net margin (17.3% vs 0.00%) and the higher return on invested capital (14.6% vs 0.00%). Across the 17 metrics below, Lantheus Holdings, Inc. leads on 14 and Amylyx Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | AMLX | LNTH | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 61.26% | 53.51% |
| Operating margin | 0.00% | 18.62% | 0.00% |
| Net margin | 0.00% | 17.28% | (2.45%) |
| Free cash flow margin | 0.00% | 26.21% | 0.00% |
| Return on equity | (74.73%) | 21.81% | (0.80%) |
| Return on assets | (66.25%) | 11.41% | (1.67%) |
| Return on invested capital | 0.00% | 14.62% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack